安旭生物收盘上涨2.41%，滚动市盈率33.53倍，总市值52.35亿元

Company Overview - Anxu Bio focuses on the research, development, production, and sales of POCT reagents and instruments [1] - The company has been recognized as a "Zhejiang Province Intellectual Property Demonstration Enterprise" and a "National Intellectual Property Advantage Enterprise" [1] - As of 2024, Anxu Bio has obtained 44 new authorized patents, including 13 invention patents, bringing the total to 305 authorized patents, of which 43 are invention patents [1] Financial Performance - As of the first quarter of 2025, Anxu Bio reported a revenue of 115 million yuan, a year-on-year decrease of 10.90% [1] - The net profit for the same period was approximately 34.03 million yuan, reflecting a year-on-year decline of 51.52% [1] - The company's gross profit margin stands at 42.32% [1] Market Position - Anxu Bio's current price-to-earnings (PE) ratio is 33.53, compared to the industry average of 54.56 and the industry median of 37.54 [2] - The company's total market capitalization is 5.235 billion yuan [1][2] - As of the first quarter of 2025, two institutions hold shares in Anxu Bio, with a total of 172,000 shares valued at 0.07 million yuan [1]